Loading…
Calidi Biotherapeutics, Inc. is projected to decline to $0.1876 by 2027, a -2% move from its current price of $0.191. CLDI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.181 | $0.1909 | $0.2013 | -0.05% |
| May 30 | $0.177 | $0.1908 | $0.2057 | -0.10% |
| May 31 | $0.1739 | $0.1907 | $0.2091 | -0.15% |
| Jun 1 | $0.1714 | $0.1906 | $0.212 | -0.20% |
| Jun 2 | $0.1692 | $0.1905 | $0.2146 | -0.25% |
| Jun 3 | $0.1672 | $0.1904 | $0.2169 | -0.30% |
| Jun 4 | $0.1654 | $0.1903 | $0.2191 | -0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1654 | $0.1903 | $0.2191 | -0.35% |
| Week 2 | $0.1555 | $0.1896 | $0.2314 | -0.71% |
| Week 3 | $0.1481 | $0.189 | $0.2411 | -1.06% |
| Week 4 | $0.1422 | $0.1883 | $0.2494 | -1.41% |
| Week 5 | $0.137 | $0.1876 | $0.2569 | -1.76% |
| Week 6 | $0.1325 | $0.187 | $0.2638 | -2.11% |
| Week 7 | $0.1284 | $0.1863 | $0.2703 | -2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Calidi Biotherapeutics, Inc. is a biotechnology company that develops targeted therapies to deliver genetic medicines to distal sites of disease.
The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova.
Calidi Biotherapeutics was founded in 2014 and is headquartered in San Diego, California.
Calidi Biotherapeutics, Inc. trades at $0.191 and operates in the Healthcare sector as a biotechnology company focused on targeted genetic medicines.
Its current market position shows a market capitalization of $3.69M and a rank of 5340.
The forecast outlines a multi-year price path with yearly averages spanning from 2026 through 2050. The 2026 avg is $0.191, and the 2050 avg is $0.7081, with a wide range of implied returns across years. Notably, 2027 shows a negative ROI of -1.8%, while several later years are projected bullish with substantial ROIs (e.g., 2028 25.2%, 2029 45.3%, 2030 40.7%, 2035 70.8%, 2040 63.6%, and 2050 270.7%).
A major floor 45.4% below — a decisive break under it would weaken the trend.
The nearest floor, 11.5% below — buyers have tended to step in here.
The nearest ceiling, 45.0% above — a clean break opens room to run.
A major ceiling 449.7% above — clearing it would confirm fresh momentum.
Key CLDI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLDI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.181 | Buy | $0.1839 | Buy |
| MA 10 | $0.1848 | Buy | $0.1872 | Buy |
| MA 20 | $0.1983 | Sell | $0.2005 | Sell |
| MA 50 | $0.2356 | Sell | $0.2997 | Sell |
| MA 100 | $0.545 | Sell | $0.6382 | Sell |
| MA 200 | $1.15 | Sell | $3.85 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.77 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -32.44 | Neutral |
| Williams %R (14) | -54.17 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -9.48 | Sell |
| Bollinger %B (20,2) | 0.39 | Neutral |
| Stochastic %K (14) | 45.83 | Neutral |
| TRIX (15) | -1.48 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 47.01 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 0.18 | Buy |
| ADX (14) | 33.59 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is NEUTRAL.
RSI14 is 40, indicating room for movement before overbought conditions. The short-term moving averages sit at SMA50 of $0.2356 and SMA200 of $1.15, highlighting near-term price alignment versus longer-term trendlines.
Key support is at $0.169 and resistance at $0.277. The 30-day price range extends from $0.1346 to $0.2711, illustrating a narrow trading window around the current level. Annualized volatility is 100%, underscoring the elevated risk in the period ahead.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.169 | $0.191 | $0.2394 | 0% | Neutral | |
| $0.1352 | $0.1876 | $0.2818 | -2% | Neutral | |
| $0.1623 | $0.2391 | $0.3816 | +25% | Bullish | |
| $0.179 | $0.2775 | $0.4643 | +45% | Bullish | |
| $0.1655 | $0.2687 | $0.4677 | +41% | Bullish | |
| $0.1363 | $0.2312 | $0.4162 | +21% | Bullish | |
| $0.1332 | $0.2355 | $0.437 | +23% | Bullish | |
| $0.1207 | $0.2221 | $0.4234 | +16% | Neutral | |
| $0.1262 | $0.2414 | $0.4718 | +26% | Bullish | |
| $0.164 | $0.3261 | $0.6519 | +71% | Bullish | |
| $0.1406 | $0.3125 | $0.6858 | +64% | Bullish | |
| $0.3186 | $0.7081 | $1.63 | +271% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.169 | $0.191 | $0.2243 | +0.00% |
| June 2026 | $0.1461 | $0.1752 | $0.2176 | -8.27% |
| July 2026 | $0.1496 | $0.1824 | $0.2323 | +4.10% |
| August 2026 | $0.154 | $0.1903 | $0.2471 | +4.33% |
| September 2026 | $0.1434 | $0.1792 | $0.2363 | -5.84% |
| October 2026 | $0.1376 | $0.1736 | $0.2322 | -3.10% |
| November 2026 | $0.1427 | $0.1818 | $0.246 | +4.71% |
| December 2026 | $0.1362 | $0.1749 | $0.2394 | -3.79% |
Click any year to see its month-by-month CLDI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Calidi Biotherapeutics, Inc.'s 2026 outlook centres on $0.191, within a $0.169 to $0.2394 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CLDI could reach as high as $0.2818, with a base case around $0.1876 and support toward $0.1352 — roughly -2% from $0.191. Price action looks broadly range-bound.
Expect CLDI to range from $0.1623 to $0.3816 through 2028. The $0.2391 average target implies a +25% move from current prices. That is up +27% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CLDI price prediction for 2029 points to an average of $0.2775 (low $0.179, high $0.4643) — a potential gain of +45% on today's $0.191. Momentum favours further upside here.
In 2030, CLDI is projected to trade between $0.1655 and $0.4677, averaging $0.2687 — a potential gain of +41% from today's $0.191. That is -3% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Calidi Biotherapeutics, Inc.'s 2031 outlook centres on $0.2312, within a $0.1363 to $0.4162 range. That is -14% versus the projected 2030 average. That marks a +21% change versus current levels. Momentum favours further upside here.
By 2032, CLDI could reach as high as $0.437, with a base case around $0.2355 and support toward $0.1332 — roughly +23% from $0.191. Buyers look set to stay in control over this stretch.
Expect CLDI to range from $0.1207 to $0.4234 through 2033. The $0.2221 average target implies a +16% move from current prices. That is -6% versus the projected 2032 average. Price action looks broadly range-bound.
The CLDI price prediction for 2034 points to an average of $0.2414 (low $0.1262, high $0.4718) — a potential gain of +26% on today's $0.191. Buyers look set to stay in control over this stretch.
In 2035, CLDI is projected to trade between $0.164 and $0.6519, averaging $0.3261 — a potential gain of +71% from today's $0.191. That is up +35% on the projected 2034 average. Momentum favours further upside here.
Calidi Biotherapeutics, Inc.'s 2040 outlook centres on $0.3125, within a $0.1406 to $0.6858 range. That is -4% versus the projected 2035 average. That marks a +64% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CLDI could reach as high as $1.63, with a base case around $0.7081 and support toward $0.3186 — roughly +271% from $0.191. Momentum favours further upside here.
Investing $1,000 in CLDI today (≈ 5,235.602094 CLDI) could be worth
$3,707.21
+$2,707.21 (+271%) by 2050 · US Dollar
Based on the average projected CLDI price of $0.71 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLDIwould be worth at today's price.
$1,000 invested in CLDI on May 27, 2025 (≈ 207.813808 CLDI) would be worth
$39.69
-$960.31 (-96.0%) today · 0.04× · US Dollar
Based on a CLDI entry price of $4.81 vs. today's $0.191.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.169 | $1,130.18 | +13.0% |
| 1 month ago | $0.238 | $802.52 | -19.7% |
| 3 months ago | $0.846 | $225.77 | -77.4% |
| 6 months ago | $1.51 | $126.49 | -87.4% |
| 1 year ago | $4.81 | $39.69 | -96.0% |
| All time (4.6y) ago | $1,173.6 | $0.16 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLDI forecast.
Our base-case forecast reaches $0.38 around 2050.
Implied market cap at $0.38: $7.34M
2030: The forecast shows an average price of $0.2687 with ROI of 40.7% and sentiment BULLISH.
2040: The forecast shows an average price of $0.3125 with ROI of 63.6% and sentiment BULLISH.
2050: The forecast shows an average price of $0.7081 with ROI of 270.7% and sentiment BULLISH.
2035: The forecast shows an average price of $0.3261 with ROI of 70.8% and sentiment BULLISH.
Overall, the path suggests rising averages and bullish sentiment in many years, with notable upside by the 2050 horizon. These figures are estimates, not guarantees, and actual results can differ.
Tap a question to reveal the answer.
Avg price $0.2687; min $0.1655; max $0.4677; ROI 40.7%; sentiment BULLISH.
The forecast shows several bullish years (e.g., 2028-2032, 2034-2035, 2040, 2050) with positive ROIs in multiple years, including 2029 (45.3%), 2030 (40.7%), and 2035 (70.8%), but 2027 shows ROI -1.8%. These are estimates, not guarantees.
2035 max is $0.6519; avg $0.3261; min $0.164. This indicates a move above $0.50 is within the max projection.
Current price is $0.191; 30-day range is $0.1346 to $0.2711; RSI 14 is 40; SMA50 is $0.2356; SMA200 is $1.15; sentiment is NEUTRAL. Annualized volatility is 100%.
Market cap $3.69M; rank 5340.
Calidi Biotherapeutics, Inc. Community Discussion
0Share your Calidi Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.